J
Jason Stavropoulos
Researcher at Abbott Laboratories
Publications - 7
Citations - 1269
Jason Stavropoulos is an academic researcher from Abbott Laboratories. The author has contributed to research in topics: In vivo & Receptor tyrosine kinase. The author has an hindex of 6, co-authored 7 publications receiving 1190 citations.
Papers
More filters
Journal ArticleDOI
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
Cherrie K. Donawho,Yan Luo,Yanping Luo,Thomas D. Penning,Joy Bauch,Jennifer J. Bouska,Velitchka Bontcheva-Diaz,Bryan F. Cox,Theodore L. DeWeese,Larry E. Dillehay,Debra Ferguson,Nayereh S. Ghoreishi-Haack,David R. Grimm,Ran Guan,Edward K. Han,Rhonda R. Holley-Shanks,Boris Hristov,Kenneth B. Idler,Ken Jarvis,Eric F. Johnson,Lawrence Kleinberg,Vered Klinghofer,Loren M. Lasko,Xuesong Liu,Kennan C. Marsh,Thomas McGonigal,Jonathan A. Meulbroek,Amanda M. Olson,Joann P. Palma,Luis E. Rodriguez,Yan Shi,Jason Stavropoulos,Alan C. Tsurutani,Gui Dong Zhu,Saul H. Rosenberg,Vincent L. Giranda,David Frost +36 more
TL;DR: ABT-888 is a potent inhibitor of PARP, has good oral bioavailability, can cross the blood-brain barrier, and potentiates temozolomide, platinums, cyclophosphamide, and radiation in syngeneic and xenograft tumor models.
Journal ArticleDOI
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.
Daniel H. Albert,Paul Tapang,Terrance J. Magoc,Lori J. Pease,David R. Reuter,Ru-Qi Wei,Junling Li,Jun Guo,Peter F. Bousquet,Nayereh S. Ghoreishi-Haack,Baole Wang,Gail Bukofzer,Yi-Chun Wang,Jason Stavropoulos,Kresna Hartandi,Amanda Niquette,Nirupama B. Soni,Eric F. Johnson,J. Owen McCall,Jennifer J. Bouska,Yanping Luo,Cherrie K. Donawho,Yujia Dai,Patrick A. Marcotte,Keith B. Glaser,Michael R. Michaelides,Steven K. Davidsen +26 more
TL;DR: ABT-869 is a structurally novel, receptor tyrosine kinase (RTK) inhibitor that is a potent inhibitor of members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor(PDGF) receptor families as mentioned in this paper.
Journal ArticleDOI
A Small-Molecule Inhibitor of Bcl-XL Potentiates the Activity of Cytotoxic Drugs In vitro and In vivo
Alex R. Shoemaker,Anatol Oleksijew,Joy Bauch,Barbara A. Belli,Tony Borre,Milan Bruncko,Thomas Deckwirth,David Frost,Ken Jarvis,Mary K. Joseph,Kennan C. Marsh,Mcclellan William J,Hugh N. Nellans,Shi-Chung Ng,Paul Nimmer,Jacqueline M. O'Connor,Tilman Oltersdorf,Weiguo Qing,Wang Shen,Jason Stavropoulos,Stephen K. Tahir,Baole Wang,Robert B. Warner,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore +26 more
TL;DR: A-385358 enhances the in vitro cytotoxic activity of numerous chemotherapeutic agents (pac litaxel, etoposide, cisplatin, and doxorubicin) in several tumor cell lines and potentiates the activity of paclitaxel in vivo.
Journal ArticleDOI
Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents.
Yunsong Tong,Jennifer J. Bouska,Paul A. Ellis,Eric F. Johnson,Joel D. Leverson,Xuesong Liu,Patrick A. Marcotte,Amanda M. Olson,Donald J. Osterling,Magdalena Przytulinska,Luis E. Rodriguez,Yan Shi,Nirupama B. Soni,Jason Stavropoulos,Sheela A. Thomas,Cherrie K. Donawho,David Frost,Yan Luo,Vincent L. Giranda,Thomas D. Penning +19 more
TL;DR: This work pursued unsaturated heterocycles to replace the saturated cyclic amine derivatives appended to the benzimidazole core to maintain high enzymatic potency and robust cellular activity in new generation PARP-1 inhibitors.
Journal Article
The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.
Joann P. Palma,Luis E. Rodriguez,Velitchka Bontcheva-Diaz,Jennifer J. Bouska,Gail Bukofzer,Milagros Colon-Lopez,Ran Guan,Kenneth Jarvis,Eric F. Johnson,Vered Klinghofer,Xuesong Liu,Amanda Olson,Mary Saltarelli,Yan Shi,Jason Stavropoulos,Gui-Dong Zhu,Thomas D. Penning,Yan Luo,Vincent L. Giranda,Saul H. Rosenberg,David Frost,Cherrie K. Donawho +21 more
TL;DR: Potentiation of TMZ activity by ABT-888 correlated with drug levels and inhibition of PARP activity in vivo, and is in Phase 1 trials using a validated ELISA based on the assay developed here to assess pharmacological effect.